Immix Biopharma (IMMX) Non-Current Assets (2020 - 2026)
Immix Biopharma (IMMX) reported Non-Current Assets of $3.5 million for Q1 2026, up 13.76% on a YoY basis from $3.1 million in Q1 2025, and down 1.7% sequentially from $3.6 million in Q4 2025.
Immix Biopharma (IMMX) Non-Current Assets (2020 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 7 years of Non-Current Assets data on file, last reported at $3.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 13.76% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.9 million (up 43.02% YoY), and the FY2025 full-year result was $3.6 million, up 31.0% from the prior year.
- Non-Current Assets eased to $3.5 million in Q1 2026, from $3.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $3.6 million in Q4 2025 to a low of $4126.0 in Q3 2022.
- A 5-year average of $1.5 million and a median of $1.4 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets soared 3411.05% in 2023 and advanced 13.76% in 2026, its largest moves.
- Tracing IMMX's Non-Current Assets over 5 years: stood at $10284.0 in 2022, then soared by 1236.15% to $137410.0 in 2023, then soared by 1901.34% to $2.8 million in 2024, then soared by 31.0% to $3.6 million in 2025, then decreased by 1.7% to $3.5 million in 2026.
- Business Quant data shows IMMX's Non-Current Assets at $3.5 million in Q1 2026, $3.6 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - | 3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.54 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 137,410.00 |
| Sep 30, 2023 | 143,271.00 |
| Jun 30, 2023 | 59,273.00 |
| Mar 31, 2023 | 178,186.00 |
| Dec 31, 2022 | 10,284.00 |
| Sep 30, 2022 | 4,126.00 |
| Jun 30, 2022 | 4,691.00 |
| Mar 31, 2022 | 5,075.00 |
| Dec 31, 2021 | 5,695.00 |
| Dec 31, 2020 | 7,361.00 |